• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Smackover Lithium Submits Royalty Application to Arkansas Oil and Gas Commission for South West Arkansas Project

    5/6/25 8:30:43 AM ET
    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals
    Industrials
    Get the next $A alert in real time by email

    LEWISVILLE, Ark., May 06, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, announced that SWA Lithium LLC has submitted an application to the Arkansas Oil and Gas Commission ("AOGC") to establish a fair and equitable lithium royalty for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties, Arkansas. The hearing is scheduled for Wednesday, May 28th, 2025, at 9:00 am CDT and is to be held at the Donald W. Reynolds Community Center Grand Hall at South Arkansas University (100 East University) in Magnolia, Arkansas.

    The application proposes a quarterly gross royalty of 2.5% that will be based on the total amount of lithium produced and the average FastMarkets North American Index Price for technical grade lithium carbonate, which is higher than comparable projects globally on a lithium carbonate equivalent ("LCE") basis. The lithium royalty will be paid to brine owners in addition to the brine fee, also referred to as the "in lieu bromine royalty," of $65.05 per acre per year, making the total proposed royalty compensation approximately 3% based on current lithium prices.

    "Working with landowners and the AOGC to establish a fair and equitable royalty is key to the SWA Project's success," said Standard Lithium's CEO, David Park, "The proposed royalty generously compensates brine owners, is fair for industry, and encourages development of the Smackover resource. The royalty is only the beginning of the economic impact this project will have for South Arkansas and the rest of the state."

    "Establishing a royalty for the SWA Project allows us to continue the path towards a final investment decision," said Allison Kennedy Thurmond, VP for US Lithium at Equinor. "The proposed royalty rate enables capital investment, infrastructure improvements, jobs, tax revenue and brings tremendous benefits to the Smackover region."

    For more information about the SWA Project and Smackover Lithium, please visit www.smackoverlithium.com

    About Standard Lithium Ltd.

    Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The Company prioritizes projects characterized by high-grade resources, robust infrastructure, skilled labor, and streamlined permitting. Standard Lithium aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated Direct Lithium Extraction ("DLE") and purification process. The Company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. In partnership with global energy leader Equinor, Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and actively exploring promising lithium brine prospects in East Texas. Standard Lithium also holds an interest in certain mineral leases in the Mojave Desert in San Bernardino County, California.

    Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol "SLI". Please visit the Company's website at www.standardlithium.com.

    About Equinor

    Equinor is an international energy company committed to long-term value creation in a low-carbon future. Equinor's portfolio of projects encompasses oil and gas, renewables and low-carbon solutions, with an ambition of becoming a net-zero energy company by 2050. Headquartered in Norway, Equinor is the leading operator on the Norwegian continental shelf and is present in around 30 countries worldwide. Equinor's partnership with Standard Lithium to mature DLE projects builds on its broad US energy portfolio of oil and gas, offshore wind, low carbon solutions and battery storage projects.

    For more information on Equinor in the US, please visit: Equinor in the US - Equinor

    Investor and Media Inquiries

    Chris Lang

    Standard Lithium Ltd.

    +1 604 409 8154

    [email protected]

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target", "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to intended development timelines, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, including approval of the royalty application submitted to the AOGC, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such forward-looking statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.



    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Agilent Technologies Inc.
    $A
    12/9/2025$170.00Buy
    Goldman
    Agilent Technologies Inc.
    $A
    12/2/2025$270.00Overweight
    Morgan Stanley
    Agilent Technologies Inc.
    $A
    10/8/2025$165.00Buy
    Rothschild & Co Redburn
    Agilent Technologies Inc.
    $A
    10/8/2025$170.00Neutral → Buy
    UBS
    Standard Lithium Ltd.
    $SLI
    7/11/2025$2.75Outperform
    Raymond James
    More analyst ratings

    $A
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gabelli Hosts 17th Annual Specialty Chemicals Symposium

    GREENWICH, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 17th Annual Specialty Chemicals Symposium in Midtown Manhattan, New York City on Thursday, March 19, 2026. The event will feature discussions with leading companies and organizations across the specialty chemicals ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Specialty Chemicals investing. Attendees will also have the opportunity to participate in one-on-one meetings with management teams, available upon request. For those who cannot attend in person, access to the symposium will be available via webcast. Investors should contact their Gabelli relations

    2/24/26 8:00:00 AM ET
    $ARQ
    $ASH
    $CC
    Major Chemicals
    Industrials
    Specialty Chemicals
    Consumer Discretionary

    Agilent to Participate in TD Cowen's 46th Annual Health Care Conference

    Agilent Technologies Inc. (NYSE:A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of soluti

    2/23/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $A
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $A
    $SLI
    SEC Filings

    View All

    Amendment: SEC Form 4 filed by V.P., Corporate Controller Gonsalves Rodney

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    1/8/26 4:05:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dolsten Mikael sold $389,511 worth of shares (2,600 units at $149.81), decreasing direct ownership by 34% to 4,973 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/3/25 4:04:44 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Zhang Jianmiao Mike covered exercise/tax liability with 208 shares, decreasing direct ownership by 2% to 11,639 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/1/25 4:36:53 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00

    12/15/25 8:55:45 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/25/26 4:06:32 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SCHEDULE 13G filed by Standard Lithium Ltd.

    SCHEDULE 13G - STANDARD LITHIUM LTD. (0001537137) (Subject)

    2/13/26 9:29:46 AM ET
    $SLI
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by Agilent Technologies Inc.

    DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:10:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard Lithium Expands Leadership Team with Appointment of General Counsel

    VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is announcing the appointment of Michael Lutgring as General Counsel, effective August 18, 2025. "We are excited to have Michael join our senior leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Michael's deep and wide-ranging experience will be critical as we strengthen our capabilities and bring further expertise in-house as we continue our growth and development as a public company." Mr. Lutgring brings over two decades of legal and strategic a

    8/18/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    Standard Lithium Announces New VP Appointments to Expand and Strengthen Senior Management

    VANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is pleased to announce the appointment of Daniel Rosen as Vice President of Strategy and Investor Relations, as well as Tim Sobel as Vice President of Health, Safety, Social and Environment ("HSSE"). "We are thrilled to welcome the additions of Daniel and Tim to our leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Dan's strategic insight and deep experience in investor relations and capital markets, as well as Tim's extensive history in ensuring that HSSE sta

    6/23/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    $A
    $SLI
    Financials

    Live finance-specific insights

    View All

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials